Can-Fite BioPharma (NYSE American: CANF) Reports Study Validating Drug Potential for Canine Osteoarthritis
Expert Analysis The recent publication of a peer-reviewed article on Piclidenoson highlights a significant advancement for Can-Fite BioPharma (NYSE American: CANF). This research underlines the promising therapeutic effects of their drug candidate, Piclidenoson, in addressing canine osteoarthritis, a large and growing market with considerable medical need. The findings suggest that Piclidenoson’s mechanism as an A3 adenosine receptor agonist could provide a novel, effective treatment option. For Can-Fite BioPharma, these results…
